Apr 21, 2003 . 20. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1.

1995, as Loftsson and Brewster, 1996.), stability (Krenn et al., 1992; Zerrouk et al.

physicochemical properties of drugs or issues of drug toxicity is well known (

resultant dehydration enthalpy is relatively less (Loftsson and Brewster, 1996;

Dec 5, 2003. and their complexes was registered in 1953 (Loftsson and Brewster, 1996).

Loftsson, T., and Brewster, M. E. (1996), Pharmaceutical applications of

cyclodextrin“, Journal of Controlled Release, 40, 251-260 (1996). 81. M.E.

Patent #: 5324718. Issued on: 06/28/1994. Inventor: Loftsson .

It has been found that CDs can be used to enhance the solubility and

commonly used as a pharmaceutical excipient, which forms an inclusion complex

complexes employing cyclodextrins (Loftsson & Brewster 1996; Stella & Rajewski

Thorsteinn Loftsson Corresponding Author Contact Information . are in dynamic

8) Loftsson T., Brewster M. E., Pharm. Technol. Eur., 5, 26?34 (1997). 9) Loftsson

Jun 12, 2000 . How to Cite. Loftsson, T. and Brewster, M. E. (1996), Pharmaceutical applications

72.7 and 99000 by forming complexes with cyclodextrin derivatives (Loftsson and

2004; Reddy et al., 2004; Loftsson and Brewster, 1996). β- cyclodextrins,

Loftsson, T. and Brewster, M.E. (1996) Pharmaceutical applications of

Loftsson, T., Brewster, M.E. (1996). Pharmaceutical applications of cyclodextrins:

68–76. 6. T Loftsson and M E Brewster, “Pharmaceutical applications of

Marcus E. Brewster Tel: +32 14 603157 . .. Loftsson T, Brewster M.

. 1994; Loftsson, 1995; Albers and Muller, 1995; Loftsson and Brewster, 1996;

resulting in increased aqueous solubility and chemical stability (Loftsson and

ability to increase the apparent solubility of hydrophobic drugs via the formation

Feb 17, 2004 . Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1.

Már Másson a, Thorsteinn Loftsson a , *, Sigrídur Jónsdóttir b, Hafrún

Chem., 39 (1996) 4775. 134. L. Prokai . K. Raghavan, T. Loftsson, ME Brewster

. and possible parenteral toxicity), the amount of cyclodextrins that can be used

energy) (Frömming and Szejtli 1994; Loftsson and Brewster 1996). Random

ME Brewster, Loftsson T (2007) Cyclodextrins as pharmaceutical solubilizers.

. Loftsson et al., 1990, Loftsson et al., 1994, Loftsson et al., 1996, Moyano et al.,

Thorsteinn Loftsson * and Hafrún Fri&z.eth;riksdóttir . and Wouessidjewe, 1996

Stabilization. THORSTEINN LOFTSSON*X AND MARCUS E. BREWSTER. † . X

(May, 1997). Loftsson and Brewster, J. Pharm. Sci., 85(10), 1017-1025 (1996). (

Uekama et al., 1994; Loftsson, 1995; Albers and Muller, 1995;. Loftsson and

2: T. LOFTSSON, M.E. BREWSTER; J. Pharm. Sci., 85, pp. 1017-1025, 1996. 3:

sion complex formation (Loftsson and Brewster 1996; Stella and Rajewski 1997;

85(10), 1017-1025 (1996); T. Loftsson and M. E. Brewster, “Cyclodextrins as

. to drug solubilization and stabilization (Loftsson and Brewster, 1996, J. Pharm.

1988; Loftsson and Brewster, 1996; Loftsson,. 1999). Side effects of the drug and

Addison Wesley Longman Limited (1996). Shenkin, P.S. and McDonald, D. Q. J.

In: Davies JED (editor). Topics in Inclusion Science Vol 5 - Cyclodextrin

. diameter of the hydrophobic cavity is approximately 4.7–5.3, 6.0–6.5, and 7.5–

The second branch of decision tree involves the use of cyclodextrin com-

Cyclodextrins are able to form water-soluble inclusion complexes with many

References. 1 T. Loftsson and M. E. Brewster, J. Pharm. Sci., 85 (1996) 1017. 2 T.

Mar 2, 2004 . Loftsson and Brewster, ;, 9(5), 26-34 (1997). (May, 1997). Loftsson and Brewster,

β-cyclodextrin (HPβCD) (Peeters et al., 2002; Davis and Brewster, 2004; . .

2011: Messner, M; Kurkov, SV; Flavià-Piera, R; Brewster, ME; Loftsson, T . ..

agents for lipophilic substances in aqueous pre- parations (Ducheˆne and

Sitemap